discovery of glp 1 GLP-1R Agonists for Weight Loss The Story of GLP-1: A

When semaglutide was approved to treat Type 2 diabestes in 2017, Novo named it Ozempic

Its Phase 2 obesity trial published in Lancet Diabetes & Endocrinology (2024) showed up to 18.7% weight loss at 46 weeks, while a separate Phase 2 MASH trial demonstrated significant MASH resolution, earning FDA Breakthrough Therapy Designation

This often leads to under-eating, which can cause nutrient deficiencies and also stalled weight loss as the body is trying to just survive on little calories

In addition to managing side effects, lifestyle changes can improve how well GLP-1 agonists work and enhance your overall experience

Patients described greater ease with walking, climbing stairs, and performing daily tasks that had previously become difficult